胰腺癌新辅助化疗的研究进展-王泽升

ModernPracticalMedicine,August2014,Vol.26,No.81052doi:10.3969/j.issn.1671-0800.2014.08.079R735.9C1671-0800(2014)08-1052-03315041Email:[e-mail]55%[1]10%20%[2]530%20%1825[3][4]1CTMRIEUSCTBRPCR0R080%BRPCR0R1R2R1[5]BRPC[6]2EUSFNAEUS-FNACT[7]1EUSBRPCEUS-FNAEUS-FNA3Oettle[8][9]80%,[10][11]1R023445-5-FU5-FU[12]5-FU[13]15-Fu[14]201482681053M.D.Anderson86400mg/m2111274%36527%[15]2010Gillen[16]1985111Meta33.3%BRPCLouvet[17]98+Kin-dler[18]43431739.517/43R082.3%14/1723.113.2BRPCBRPC2011Conroy[19]Folfirinox+++BRPC[20]2211.7BRPCZhu[21]315-FuBRPC5MARéCHALhENT1hENT1[22]hENT1hENT1JohnhENT1hENT15FU/FASarah95ERCC1RRM2[23]/[1]SaifMW.Newdevelopmentsinthetreat-mentofpancreaticcancer.Highlightsfromthe44thASCOAnnualMeeting[J].JOP,2008,9(4):391-397.[2]JemalA,SiegelR,WardE,etal.Cancerstatistics,2009[J].CACancerJClin,2009,59(4):225-249.[3]SchnelldorferT,WareAL,SarrMG,etal.Long-termsurvivalafterpancreatoduodenec-tomyforpancreaticadenocarcinoma:iscurepossible[J]AnnSurg,2008,247(3):456-462.[4]CampbellPJ,YachidaS,MudieLJ,etal.Thepatternsanddynamicsofgenomicin-stabilityinmetastaticpancreaticcancer[J].Nature,2010,467(7319):1109-1113.[5]ZervosEE,RosemurgyAS,Al-SaifO,etal.Surgicalmanagementofearly-stagepancre-aticcancer[J].CancerControl,2004,11(1):23-31.[6]PingpankJF,HoffmanJP,RossEA,etal.Effectofpreoperativechemoradiotherapyonsurgicalmarginstatusofresectedaden-ocarcinomaoftheheadofthepancreas[J].JGastrointestSurg,2001,5(2):121-130.[7]MicamesC,JowellPS,WhiteR,etal.Lowerfrequencyofperitonealcarcinoma-tosisinpatientswithpancreaticcancerdi-agnosedbyEUS-guidedFNAvs.percu-taneousFNA[J].GastrointestEndosc,2003,58(5):690-695.[8]VanLaethemJL,HammelP,MornexF,etal.Adjuvantgemcitabinealoneversusgemcitabine-basedchemoradiotherapyaftercurativeresectionforpancreaticcancer:arandomizedEORTC-40013-22012/FFCD-9203/GERCORphaseIIstudy[J].JClinOncol,2010,28(29):4450-4456.[9]UenoH,KosugeT,MatsuyamaY,etal.ArandomisedphaseIIItrialcomparinggem-citabinewithsurgery-onlyinpatientswithresectedpancreaticcancer:JapaneseStu-dyGroupofAdjuvantTherapyforPancreaticCancer[J].BrJCancer,2009,101(6):908-915.[10],,.[J].:,2011,14:1-4[11]RussAJ,WeberSM,RettammelRJ,etal.Impactofselectionbiasontheutilizationofadjuvanttherapyforpancreasadenoc-arcinoma[J].AnnSurgOncol,2010,17(2):371-376.[12]NeoptolemosJP,DunnJA,StockenDD,etal.EuropeanStudyGroupforPancreaticCancer.AdjuvantchemoradiotherapyandchemotherapyinresectablepancreaticModernPracticalMedicine,August2014,Vol.26,No.81054cancer:arandomisedcontrolledtrial[J].Lancet,2001,358(9293):1576-1585.[13]CullinanS,MoertelCG,WieandHS,etal.AphaseIIItrialonthetherapyofadvan-cedpancreaticcarcinoma.EvaluationsoftheMallinsonregimenandcombined5-fluorouracil,doxorubicin,andcisplatin[J].Cancer,1990,65(10):2207-2212.[14]BurrisHA3rd,MooreMJ,AndersenJ,etal.Improvementsinsurvivalandclinicalbenefitwithgemcitabineasfirst-linether-apyforpatientswithadvancedpancreascancer:arandomizedtrial[J].JClinOn-col,1997,15(6):2403-2413.[15]EvansDB,VaradhacharyGR,CraneCH,etal.Preoperativegemcitabine-basedchemo-radiationforpatientswithresectableaden-ocarcinomaofthepancreatichead[J].JClinOncol,2008,26(21):3496-3502.[16]GillenS,SchusterT,MeyerZumBüschenfeldeC,etal.Preoperative/neoadjuvanttherapyinpancreaticcancer:asystematicreviewandmeta-analysisofresponseandresec-tionpercentages[J].PLoSMed,2010,7(4):e1000267.[17]LouvetC,LabiancaR,HammelP,etal.Gemcitabineincombinationwithoxali-platincomparedwithgemcitabinealoneinlocallyadvancedormetastaticpancre-aticcancer:resultsofaGERCORandGISCADphaseIIItrial[J].JClinOncol,2005,23(15):3509-3516.[18]KindlerHL,NiedzwieckiD,HollisD,etal.Gemcitabineplusbevacizumabcom-paredwithgemcitabineplusplaceboinpatientswithadvancedpancreaticcancer:phaseIIItrialoftheCancerandLeukemiaGroupB(CALGB80303)[J].JClinOn-col,2010,28(22):3617-3622.[19]ConroyT,DesseigneF,YchouM,etal.FOLFIRINOXversusgemcitabineformetastaticpancreaticcancer[J].NEnglJMed,2011,364(19):1817-1825.[20]FarisJE,BlaszkowskyLS,McDermottS,etal.FOLFIRINOXinlocallyadvancedpancreaticcancer:theMassachusettsGen-eralHospitalCancerCenterexperience[J].Oncologist,2013,18(5):543-548.[21]ZhuCP,ShiJ,ChenYX,etal.Gemcita-bineinthechemoradiotherapyforlocallyadvancedpancreaticcancer:ameta-analy-sis[J].RadiotherOncol,2011,99(2):108-113.[22]MaréchalR,BachetJB,MackeyJR,etal.Levelsofgemcitabinetransportandme-tabolismproteinspredictsurvivaltimesofpatientstreatedwithgemcitabineforpan-creaticadenocarcinoma[J].Gastroenter-ology,2012,143(3):664-674.[23]FisherSB,PatelSH,BagciP,etal.Ananalysisofhumanequilibrativenucleo-sidetransporter-1,ribonucleosidereduc-ta-sesubunitM1,ribonucleosidereducta-sesubunitM2,andexcisionrepaircross-complementinggene-1expressioninpati-entswithresectedpancreasaden-ocarcin-oma:implicationsforadjuvanttreatment[J].Cancer,2013,119(2):445-453.2013-10-14doi:10.3969/j.issn.1671-0800.2014.08.080R551.3C1671-0800(2014)08-1054-03315040113Email:[e-mail]1BMSCs1.1BMSCsMSCsBMSCsMSCsMSCsMSCs[1]1.2BMSCsBMSCs41232412341998Qiu[2]Glowacki[3]BMSCs2ECM2.1ECMECM